California Healthcare Institute has released a new report on the importance of promoting antibiotic discovery and development to combat antibiotic resistance and emerging pathogens that are highly resistant to known antibiotics.
CHI reports that as antimicrobial resistance has increased, the production of FDA-approved antibacterial products has decreased over the past 25 years and the number of products in clinical development remains small. The report highlights the need for regulatory reform in order to boost innovation in this arena.
"While the need for effective antibiotics is clear, the drug development pipeline has not kept pace," said CHI President and CEO David L. Gollaher. "The most important barrier to investment is the FDA regulatory process but we are confident that the FDA has the power and ability to solve this problem."
The report also discusses the Generating Antibiotic Incentives Now Act, a bipartisan effort to spur development of new antibiotics. To read the report, "Promoting Antibiotic Discovery and Development," in full, click here.
CHI reports that as antimicrobial resistance has increased, the production of FDA-approved antibacterial products has decreased over the past 25 years and the number of products in clinical development remains small. The report highlights the need for regulatory reform in order to boost innovation in this arena.
"While the need for effective antibiotics is clear, the drug development pipeline has not kept pace," said CHI President and CEO David L. Gollaher. "The most important barrier to investment is the FDA regulatory process but we are confident that the FDA has the power and ability to solve this problem."
The report also discusses the Generating Antibiotic Incentives Now Act, a bipartisan effort to spur development of new antibiotics. To read the report, "Promoting Antibiotic Discovery and Development," in full, click here.
Related Articles on Antibiotics:
New Protocol Reduces Sternum Infections in Children by 61%
17 Steps to an Award-Winning C. Diff Reduction Program
Intervention Improved Antibiotic Prophylaxis Compliance But Not Infection Rates